What is the recommended treatment for shingles (herpes zoster), including antiviral therapy and pain management?

Treatment of Shingles (Herpes Zoster)

Start oral antiviral therapy with valacyclovir or famciclovir within 72 hours of rash onset for all immunocompetent patients, as these agents provide superior pain reduction compared to acyclovir and offer more convenient dosing regimens. 1

Antiviral Therapy

First-Line Treatment for Immunocompetent Adults

The evidence strongly supports valacyclovir or famciclovir as preferred agents over acyclovir:

• Valacyclovir reduces herpes zoster-associated pain by 36% at 21-30 days (NNT=3) compared to acyclovir, with sustained benefit up to 112 days 1
• Famciclovir reduces pain risk by 46% at 28-30 days (NNT=3) compared to acyclovir 1
• Both agents have superior pharmacokinetics and more convenient dosing schedules than acyclovir 1

Initiate treatment within 72 hours of rash onset to reduce severity of infection, duration of eruptive phase, and intensity of acute pain 2, 3

Dosing Regimens

While the provided evidence focuses on comparative efficacy rather than specific dosing, standard practice based on the superior outcomes demonstrated includes:

• Treatment duration should be 7-10 days 2, 3
• Earlier initiation (ideally within 24-72 hours) maximizes therapeutic benefit 2

Severe Disease or Complications

Administer intravenous acyclovir 5-10 mg/kg every 8 hours for 5-7 days for patients requiring hospitalization due to: 4

• Disseminated infection
• Pneumonitis
• Hepatitis
• CNS complications (meningitis or encephalitis)

Special Populations

Immunocompromised Patients

Immunosuppressed patients require more aggressive antiviral therapy due to higher risk of prolonged, severe, and atypical disease: 4

• Higher doses of antivirals are beneficial (e.g., acyclovir 400 mg orally 3-5 times daily) 4
• Intravenous acyclovir is required for complicated herpes zoster, including multi-dermatomal, ophthalmic, visceral, or disseminated disease 4
• Treatment should continue for minimum 7-10 days and until skin vesicles resolve 4
• Temporarily discontinue immunosuppressive therapy in severe cases of disseminated varicella or herpes zoster 4

Acyclovir-Resistant Cases

If lesions persist despite appropriate acyclovir treatment in immunocompromised patients: 4

• Suspect acyclovir resistance (all acyclovir-resistant strains are also resistant to valacyclovir, and most to famciclovir) 4
• Switch to foscarnet 40 mg/kg IV every 8 hours until clinical resolution 4
• Topical cidofovir gel 1% applied once daily for 5 consecutive days may be effective 4

Pain Management

Acute Pain Control

Combine antiviral therapy with appropriate analgesics for acute zoster pain control: 2, 3

• Analgesics should be initiated alongside antivirals 2
• The primary goal is symptom control during the acute phase 2

Postherpetic Neuralgia (PHN) Prevention and Treatment

PHN occurs in approximately 20% of patients and is defined as pain sustained for at least 90 days after acute herpes zoster: 2

For established PHN, use: 2

• Topical agents: Lidocaine patches or capsaicin
• Systemic agents: Gabapentin, pregabalin, or tricyclic antidepressants

The only proven measures to prevent PHN are: 3

• Varicella-zoster virus vaccination (preventive)
• Early treatment with famciclovir or valacyclovir 3

Adjunctive Measures

Skin Care

• Maintain good skin care practices to promote healing and prevent secondary bacterial infection 3
• Monitor for bacterial superinfection as a potential complication 4

Novel Approaches

Recent evidence suggests ultrasound-guided paravertebral blocks with novel analgesic combinations (including parecoxib and methylcobalamin) may provide superior sustained analgesia for thoracic herpes zoster, though this requires specialized expertise 5

Critical Pitfalls to Avoid

• Do not delay treatment waiting for laboratory confirmation in typical presentations—diagnosis is clinical 6, 2
• Do not use topical acyclovir—it is substantially less effective than oral therapy 4
• Do not assume immunocompetent dosing is adequate for HIV-infected or other immunocompromised patients 4
• Do not continue standard antivirals if lesions persist in immunocompromised patients—consider resistance and switch to foscarnet 4
• Do not restart immunosuppression in severe cases until antiviral therapy is established and vesicles have resolved 4